Topics A-Z [1]
Topic hub pages are designed to make it easy to find all of our content by topic. We are continuously adding new pages to this section. If you are looking for something specific and cannot find it below, try using the A-Z listing.
- Cannabis [2]
- Cannabis policy [3]
- Cocaine [4]
- COVID-19 [5]
- Darknet [6]
- Driving and drugs [7]
- Drug checking [8]
- Drug consumption facilities [9]
- Drug markets [10]
- Drug-related deaths and mortality [11]
- Drug-related infectious diseases [12]
- EU4Monitoring Drugs (EU4MD) [13]
- General population surveys [14]
- Harm reduction [15]
- Hepatitis C [16]
- Heroin [17]
- Hospital emergencies [18]
- Key epidemiological indicators [19]
- Law and legal aspects [20]
- Mental health (comborbidity) [21]
- Naloxone (take-home naloxone) [22]
- New psychoactive substances [23]
- Prevalence and patterns of use [24]
- Prevention of drug use [25]
- Prison [26]
- Problem drug use [27]
- Production of drugs [28]
- Public expenditure [29]
- Synthetic cannabinoids [30]
- Trafficking of drugs [31]
- Treatment demand [32]
- Treatment of drug use [33]
- Wastewater analysis [34]
- Women, gender and drugs [35]
- Young people [36]
These pages make it easy to explore all of our resources by topic.
Note that we are currently updating this section of our website and will be adding more topics pages over the coming months.
- A
- amphetamine
- B
- barbiturates, drug profile [39]
- benzodiazepines, drug profile [40]
- benzodiazepine mis-use among high-risk opioid users in Europe [41]
- Best practice portal — what works in prevention, treatment, harm reduction and social reintegration (under 'Best practice' ⇝) [42]
- BZP and other piperazines, drug profile [43]
- C
- cannabis [2]
- characteristics of frequent and high-risk cannabis users [44]
- cannabis, drug profile [45]
- markets, new developments in Europe's cannabis market [46]
- models for the legal supply of cannabis — recent developments [47]
- cannabis policy topic hub [3]
- policy, status of and recent changes [48]
- resin market: changes in Europe [49]
- cocaine [4]
- consumption rooms — see 'drug consumption rooms'
- control status by drug — see 'drug profiles'
- COVID-19 [5]
- cannabis [2]
- D
- darknet/cryptomarkets [6]
- deaths and overdose
- drug consumption rooms, an overview of provision and evidence [54]
- drug-related deaths and mortality key indicator (under 'Our activities' ⇝>) [55]
- drug overdose deathss in Europe, Frequelty asked questions (FAQ) [56]
- emergency health consequences of cocaine use in Europe [51]
- preventing overdose deaths in Europe ( 'Perspectives on drugs series') [57]
- prevention of drug-related deaths [58]
- take-home naloxone [22]
- drug checking [8]
- drug markets
- darknet/cryptomarkets [6]
- drug markets [10]
- production of drugs [28]
- trafficking of drugs [31]
- drug profiles — scientific descriptions of drugs including chemistry, pharmacology, synthesis, precursors and control status [59]
- amphetamine drug profile [37]
- barbiturates drug profile [39]
- benzodiazepines drug profile [40]
- BZP and other piperazines drug profile [43]
- cannabis drug profile [45]
- cocaine and crack drug profile [50]
- fentanyl drug profile [60]
- hallucinogenic mushrooms drug profile [61]
- heroin drug profile [62]
- khat drug profile [63]
- LSD drug profile [64]
- MDMA ('ecstasy') drug profile [65]
- methamphetamine drug profile [66]
- salvia divinorum drug profile [67]
- synthetic cannabinoids and 'Spice' drug profile [68]
- synthetic cathinones drug profile [69]
- synthetic cocaine derivatives drug profile [70]
- volatile substances drug profile [71]
- driving and drugs
- Drug consumption facilities [9]
- E
- ecstasy —see 'MDMA'
- EU4Monitoring Drugs (EU4MD) [13]
- European Drug Report — annual overview of trends, data and analysis of the drug situation in Europe [74]
- European Legal Database on Drugs (ELDD) [75]
- European Union (EU)
- events (see meetings and events)
- F
- G
- H
- hallucinogenic mushrooms
- harm reduction — see 'health and social responses'
- health and social responses [79]
- cocaine dependence, treatment for — reviewing current evidence [53]
- drug consumption rooms, an overview of provision and evidence [54]
- harm reduction [15]
- Health and social responses guide [79]
- hepatitis C treatment for injecting drug users [80]
- Internet-based drug treatment [81]
- legal framework of opioid substitution treatment (OST) [82]
- methamphetamine users, health and social responses for [83]
- monitoring drug treatment (under 'Our activities' ⇝) [84]
- monitoring harm reduction (under 'Our activities' ⇝) [85]
- monitoring health and social responses (under 'Our activities' ⇝) [86]
- monitoring social reintegration (under 'Our activities' ⇝) [87]
- opioid substitution treatment: strategies to prevent the diversion of [88]
- preventing overdose deaths in Europe [89]
- Prevention topics page [25]
- hepatitis — see 'infectious diseases'
- heroin [17]
- I
- infectious diseases
- J K L
- key epidemiological indicators [19]
- khat, drug profile [63]
- law and legal aspects [20]
- LSD, drug profile [64]
- M
- MDMA
- meetings and events
- methamphetamine
- Mental health and drugs (comorbidity) [21]
- Modelling [102]
- N
- naloxone [22]
- national data and country information (under 'Countries' ⇝) [103]
- needle and syringe programmes (NSP), legal framework of [104]
- neuroscience [105]
- new psychoactive substances (NPS) [23]
- action on new drugs (under 'Our activities' ⇝) [106]
- BZP and other piperazines, drug profile [43]
- fentanyl, drug profile [60]
- health responses to NPS [107]
- legal approaches to controlling [96]
- khat, drug profile [63]
- salvia divinorum, drug profile [67]
- synthetic cannabinoids [30]
- synthetic cathinones, injection of [108]
- O
- opioids
- opioid substitution treatment (OST) — see 'health and social responses'
- overdoses — see 'deaths and overdose'
- Q P R
- Partners (under 'About' ⇝) [111]
- European Parliament partner [112]
- Council of the European Union partner [113]
- European Commission partner [114]
- European Police Office (Europol) partner [115]
- European Centre for Disease Control (ECDC) partner [116]
- European Medicines Agency (EMA) partner [117]
- Eurojust partner [118]
- European Police College (CEPOL) partner [119]
- Reitox network partner [120]
- United Nations Office on Drug and Crime (UNODC) partner [121]
- Joint United Nations Programme on HIV/AIDS (UNAIDS) partner [122]
- World Health Organisation (WHO) partner [123]
- Pompidou Group partner [124]
- Maritime Analysis and Operation Centre–Narcotics (MAOC-N) partner [125]
- The International Criminal Police Organization (Interpol) partner [126]
- World Customs Organisation (WCO) partner [127]
- Inter-American Drug Abuse Control Commission (CICAD) [128]
- European School Survey Project on Alcohol and Other Drugs (ESPAD) partner [129]
- Candidate and potential candidate countries partners [130]
- Neighbouring countries and Russia partners [131]
- penalties, drug law penalties at a glance [97]
- Perspectives on drugs series — topical analyses providing deeper insights into a selection of important issues
- benzodiazepine mis-use among high-risk opioid users in Europe [41]
- cannabis: characteristics of frequent cannabis users [44]
- cannabis: legal supply [47]
- cannabis market in Europep [46]
- cannabis resin market: changes in Europe [49]
- cocaine: emergencies related to cocaine-use [51]
- cocaine: trafficking to Europe [52]
- comorbidity of drug use and mental health disorders [132]
- drug consumption rooms, an overview of provision and evidence [54]
- EU Drugs Strategy 2013–20 [133]
- hepatitis C treatment for injecting drug users [80]
- heroin: trends in heroin use [110]
- injection of synthetic cathinones [108]
- internet-based drug treatment [81]
- mass media campaigns — do they work? [134]
- new psychoactive substances: health responses to [107]
- new psychoactive substances: legal approaches to controlling [96]
- opioid substitution treatment: strategies to prevent the diversion of [88]
- opioid trafficking routes from Asia to Europe [109]
- overdose deaths: preventing overdose deaths [57]
- psychosocial interventions [135]
- responses for methamphetamine users [83]
- synthetic cannabinoids in Europe [136]
- synthetic drug production in Europe [38]
- treatment for cocaine dependence [53]
- wastewater analysis and drugs — a European multi-city study [137]
- policy [138]
- policy evaluation [139]
- precursors
- prevalence and patterns of drug use [24]
- prevention
- prison
- production — see 'supply and production'
- public expenditure [143]
- psychosocial interventions [135]
- research, drug-related (under 'Our activities' ⇝) [144]
- responses — see 'health and social responses'
- Partners (under 'About' ⇝) [111]
- S
- salvia divinorum, drug profile [67]
- scientific paper award (under 'Our activities' ⇝) [145]
- social reintegration — monitoring (under 'Our activities' ⇝) [87]
- statistics and data (under 'Data' ⇝) [146]
- strategies and action plans [147]
- supply, markets and production
- controlled deliveries, legal aspects [148]
- drug markets [10]
- models for the legal supply of cannabis — recent developments [47]
- new psychoactive substances, legal approaches to controlling [96]
- precursor offences, penalties for [141]
- synthetic drug production in Europe [38]
- trafficking, penalties for [149]
- synthetic cannabinoids
- synthetic cathinones
- synthetic cathinones, [69]drug profile [69]
- injection of synthetic cathinones [108]
- T
- trafficking of drugs [31]
- treatment
- U V W
- volatile substances, drug profile [71]
- wastewater analysis
- women and gender issues [35]
- X Y Z
- young people